Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + Durvalumab Neoadjuvant and Adjuvant CCRT in Resectable or Borderline Resectable Pancreatic Cancer
KCT0003167Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, durvalumab in Pancreatic neoplasia, pancreatic cancer (PC), sponsored by AstraZeneca. Started Nov 2018; status: recruiting.
02
Drugs
gemcitabinedurvalumab
03
Conditions
Pancreatic neoplasiapancreatic cancer (PC)
Beyond the preview
Go deeper on KCT0003167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003167.